Jefferies Group’s NovoCure NVCR Stock Holding History

Jefferies Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,900	Closed	-$569K	–	1892
2021 Q3	$569K	Buy	+4,900	New	+$741K	﹤0.01%	1181
2021 Q1	–	Sell	-13,600	Closed	-$2.35M	–	1875
2020 Q4	$2.35M	Buy	+13,600	New	+$1.86M	0.02%	656
2020 Q3	–	Sell	-35,000	Closed	-$2.08K	–	1485
2020 Q2	$2.08K	Buy	+35,000	New	+$2.3M	0.02%	535
2019 Q2	–	Sell	-6,113	Closed	-$294K	–	2774
2019 Q1	$294K	Buy	+6,113	New	+$294K	﹤0.01%	1806
2017 Q4	–	Sell	-325,000	Closed	-$6.45M	–	2708
2017 Q3	$6.45M	Buy	+325,000	New	+$6.39M	0.04%	423
2017 Q2	–	Sell	-10,394	Closed	-$84K	–	2453
2017 Q1	$84K	Buy	+10,394	New	+$75.1K	﹤0.01%	2146

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's NVCR Position: Q4 2021 in Review

Jefferies Group sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 4,900 shares — an estimated $569K sold.

Jefferies Group first reported a position in NVCR in Q1 2017 and held it in 6 quarters. The position peaked at $6.45M in Q3 2017. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

Jefferies Group reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
Jefferies Group sold 4,900 NovoCure shares in Q4 2021, an estimated $569K.
Jefferies Group first reported a position in NovoCure in Q1 2017 and held it in 6 quarters.
Jefferies Group's NovoCure position peaked at $6.45M in Q3 2017.
311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.